Illumina, Inc.
San Diego
California
United States
998 articles about Illumina, Inc.
-
The gene sequencing industry has really taken off in recent years. Here's a look at the top five genome sequencing companies, ranked by revenue.
-
Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health
9/29/2022
Illumina, Inc. announced the launch of the NovaSeq™ X Series, new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing.
-
Illumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum
9/29/2022
Illumina, Inc. announced multiple breakthrough sequencing innovations at its inaugural Illumina Genomics Forum.
-
Illumina Genomics Forum Sold Out, Announces Opportunity to View Innovation Roadmap Session via Livestream
9/26/2022
Illumina, Inc. announced that its inaugural Illumina Genomics Forum, being held in San Diego from September 28 through October 1, is sold out.
-
Illumina Genomics Forum to Feature Nobel Laureate Frances Arnold as part of Distinguished Panel on How the Genomics Revolution Is Transforming Patient Care
9/19/2022
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will convene a panel titled "Clinical Genomics Is Now. Are You Ready?" at its inaugural Illumina Genomics Forum (IGF), moderated by Nobel laureate and chemical engineer Frances Arnold of the California Institute of Technology.
-
Illumina to Host Upcoming Investor Day
9/19/2022
Illumina, Inc. will host its 2022 Investor Day on Monday, October 3rd starting at 8:00am Pacific Time in San Diego, CA.
-
Illumina Accelerator Invests in the Fifth Global Funding Cycle of Startups Advancing Breakthrough Therapeutics, Diagnostics, Women's Health, and Sustainable Agriculture Applications
9/14/2022
Illumina, Inc. announced that it has invested in six genomics startups for the fifth global funding cycle of Illumina Accelerator in the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator is a world-class company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.
-
Illumina Genomics Forum to Convene Leading Visionaries to Explore Architecting Health's Radically New Infrastructure
9/12/2022
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that it will convene a panel of leading visionaries, titled "Architecting Health's Radically New Infrastructure," as part of its inaugural Illumina Genomics Forum being held in San Diego from September 28 through October 1.
-
The Administrative Law Judge overseeing the FTC’s challenge of Illumina’s acquisition of Grail rejected the regulator’s anti-competition argument, Illumina announced Thursday.
-
Illumina Deepens Commitment to Customers in China with New Manufacturing Site
8/30/2022
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the opening of its first manufacturing site in China.
-
Illumina Genomics Forum to Feature Tennis Legend Chris Evert on the Role Genomics Played in her Cancer Fight
8/29/2022
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature International Tennis Hall of Fame member Chris Evert as a special guest at its inaugural Illumina Genomics Forum (IGF) on October 1.
-
Illumina Genomics Forum to Feature 23andMe Co-founder and CEO Anne Wojcicki
8/22/2022
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that it will feature Anne Wojcicki, co-founder and CEO of personal genomics company 23andMe, at its inaugural Illumina Genomics Forum on October 1.
-
Illumina Genomics Forum to Feature American Cancer Society CEO Karen Knudsen on the Future of Cancer Genomics
8/15/2022
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will feature Dr. Karen Knudsen, CEO of the American Cancer Society, at its inaugural Illumina Genomics Forum (IGF) on October 1.
-
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2022
8/11/2022
Illumina, Inc. announced its financial results for the second quarter of fiscal year 2022, which include consolidated financial results for GRAIL.
-
Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics
8/8/2022
Illumina, Inc. (NASDAQ: ILMN), today announced that on September 30, its Illumina Genomics Forum (IGF) will feature Bill Gates, co-chair of the Bill & Melinda Gates Foundation, who will deliver a keynote address on the remarkable potential of genomics to change the trajectory of global health.
-
Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities
7/27/2022
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the release of Illumina DRAGEN™ v4.0, its most accurate and comprehensive secondary analysis platform.
-
Illumina to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
7/14/2022
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2022 following the close of market on Thursday, August 11, 2022.
-
Illumina Among First in the World to Receive Approval of Science-Based Net-Zero Target
7/14/2022
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced it is among the first group of companies worldwide to receive approval of its net-zero targets by the Science Based Targets initiative.
-
Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health
6/28/2022
Illumina, Inc. announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to providing match funding to startups graduating from Illumina Accelerator Cambridge with the aim to advance breakthroughs in human health.
-
Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome
6/22/2022
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the launch of a research test, codeveloped with Merck.